Abbott Laboratories (NYSE: ABT) is a healthcare company, listed on the NYSE. Alpha Stocks Insight has published 2 articles on ABT since Friday, July 17, 2026, most recently "Abbott Agrees to $670M Settlement Covering 2,000 NEC Claims on Preterm Infant Formula (NYSE: ABT)" on Friday, August 21, 2026. Coverage to date spans Health Care and Earnings Report, tracking ABT's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Abbott is paying $670M to resolve roughly 2,000 NEC-related claims tied to its specialty preterm infant formulas, bypassing the appeals process.
A 58% gross margin and 2.3% EPS beat sent Abbott shares up nearly 12%, as management raised its full-year profit outlook on accelerating device sales.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.